Zhang Lei, Wang Ping-Er, Ying Jun, Jin Xing, Luo Cheng, Xu Taotao, Xu Shibing, Dong Rui, Xiao Luwei, Tong Peijian, Jin Hongting
Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhou, China.
The First College of Clinical Medicine, Zhejiang Chinese Medical UniversityHangzhou, China.
Front Pharmacol. 2017 Sep 5;8:611. doi: 10.3389/fphar.2017.00611. eCollection 2017.
Yougui pills (YGPs) have been used for centuries in the treatment of Chinese patients with Kidney-Yang Deficiency Syndrome. Despite the fact that the efficiency of YGPs on treating osteoarthritis has been verified in clinic, the underlying mechanisms are not totally understood. The present study observes the therapeutic role of YGPs and mechanisms underlying its chondroprotective action in osteoarthritic cartilage. To evaluate the chondroprotective effects of YGPs, we examined the impact of orally administered YGPs in a model of destabilization of the medial meniscus (DMM). Male C57BL/6J mice were provided a daily treatment of YGPs and a DMM surgery was performed on the right knee. At 12 weeks post-surgery, the joints were harvested for tissue analyses, including histomorphometry, OARSI scoring, micro-CT and immunohistochemistry for COL-2, MMP-13 and pSMAD-2. We also performed the relative experiments mentioned above in mice with conditional knockout ( mice) in articular cartilage. To evaluate the safety of YGPs, hematology was determined in each group. Amelioration of cartilage degradation was observed in the YGPs group, with increases in cartilage area and thickness, proteoglycan matrix, and decreases in OARSI score at 12 weeks post surgery. In addition, reduced BV/TV and Tb. Th, and elevated Tb. Sp were observed in DMM-induced mice followed by YGPs treatment. Moreover, the preservation of cartilage correlated with reduced MMP-13, and elevated COL-2 and pSMAD-2 protein expressional levels were also revealed in DMM-induced mice treated with YGPs. Similarly, mice exhibited significant OA-like phenotype. However, no significant difference in cartilage structure was observed in mice after YGPs treatment. Interestingly, no obvious adverse effects were observed in mice from each group based on the hematologic analyses. These findings suggested that YGPs could inhibit cartilage degradation through enhancing TGF-β/Smad signaling activation, and be considered a good option for the treatment of osteoarthritis.
右归丸(YGPs)已在中国用于治疗肾阳虚证患者数百年。尽管右归丸治疗骨关节炎的疗效已在临床上得到验证,但其潜在机制尚未完全明确。本研究观察右归丸的治疗作用及其在骨关节炎软骨中软骨保护作用的潜在机制。为了评估右归丸的软骨保护作用,我们在半月板不稳定(DMM)模型中检测了口服右归丸的影响。雄性C57BL/6J小鼠每日接受右归丸治疗,并对其右膝进行DMM手术。术后12周,采集关节进行组织分析,包括组织形态计量学、OARSI评分、显微CT以及对Ⅱ型胶原(COL-2)、基质金属蛋白酶-13(MMP-13)和磷酸化Smad2(pSMAD-2)进行免疫组化分析。我们还在关节软骨条件性敲除小鼠中进行了上述相关实验。为了评估右归丸的安全性,测定了每组小鼠的血液学指标。术后12周,在右归丸组观察到软骨降解得到改善,软骨面积和厚度、蛋白聚糖基质增加,OARSI评分降低。此外,在接受右归丸治疗的DMM诱导小鼠中,观察到骨体积分数(BV/TV)和骨小梁厚度(Tb.Th)降低,骨小梁间距(Tb.Sp)升高。此外,在接受右归丸治疗的DMM诱导小鼠中,还发现软骨的保留与MMP-13的降低以及COL-2和pSMAD-2蛋白表达水平的升高相关。同样,条件性敲除小鼠表现出明显的骨关节炎样表型。然而,右归丸治疗后,条件性敲除小鼠的软骨结构未观察到显著差异。有趣的是,根据血液学分析,每组小鼠均未观察到明显的不良反应。这些结果表明,右归丸可通过增强转化生长因子-β/ Smad信号激活来抑制软骨降解,可被认为是治疗骨关节炎的一个良好选择。